RMS13: A Phase II Trial Using Risk-Adapted Proton Beam Radiation and Surgery With Addition of Antiangiogenic Maintenance Chemotherapy in Intermediate-Risk Rhabdomyosarcoma
JCO Oncology Advances · 2026-07 · 3 (3)
DOI: 10.1200/oa-26-00060 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-07. Verfasst von Jessica Gartrell und 15 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Outcomes for intermediate-risk (IR) rhabdomyosarcoma (RMS) have remained unchanged for decades. More active chemotherapy regimens, improvements in local control, and the role of maintenance therapy (MTC) remain critical therapeutic questions. RMS13 assessed the safety and efficacy of a risk-adapted local therapy paradigm incorporating proton radiotherapy (RT) and novel MTC comprising sorafenib, bevacizumab, and oral cyclophosphamide (CBvSor) with a vincristine, dactinomycin, and cyclophosphamide (VAC) chemotherapy backbone. PATIENTS AND METHODS We report outcomes for patients with IR RMS enrolled on a multicenter phase II trial evaluating risk-adapted local therapy and MTC. Patients received 12 cycles of VAC followed by four to six cycles of CBvSor in MTC-eligible patients. Tumor status at RT initiation determined RT dose. Five-year event-free survival (EFS), overall survival (OS), disease-free survival (DFS), and local failure (LF) are reported. RESULTS Forty-five patients enrolled, of whom 35 were eligible for MTC at study entry. Twenty-three patients completed at least four cycles of MTC; however, only 18 of 24 completed treatment with all three agents. Five-year EFS and OS were 68.8% (95% CI, 0.57 to 0.84) and 75.2% (95% CI, 0.63 to 0.89), respectively. Among those receiving ≥3 MTC cycles (n = 24), 5-year DFS was 70.8% (95% CI, 0.55 to 0.92). In patients meeting European Pediatric Soft Tissue Sarcoma Group RMS2005 high-risk criteria, DFS was 82.4%. No LF occurred after margin-negative surgery; LF was 4.8% for all patients receiving local control. Five of six patients with fusion-positive N1 disease recurred. The trial closed early due to a prespecified stopping rule, with MTC completion
Zitieren
APA
Gartrell, J., Patni, T., Li, Y., Indelicato, D. J., Federico, S. M., Davidoff, A. M., Helmig, S., Stewart, E., Tinkle, C. L., Lucas, J. T., McCarville, M. E., Sandler, E., Albritton, K., Hua, C., Pappo, A. S., & Krasin, M. J. (2026). RMS13: A Phase II Trial Using Risk-Adapted Proton Beam Radiation and Surgery With Addition of Antiangiogenic Maintenance Chemotherapy in Intermediate-Risk Rhabdomyosarcoma. JCO Oncology Advances, 3(3). https://doi.org/10.1200/oa-26-00060
Vancouver
Gartrell J, Patni T, Li Y, Indelicato DJ, Federico SM, Davidoff AM, et al. RMS13: A Phase II Trial Using Risk-Adapted Proton Beam Radiation and Surgery With Addition of Antiangiogenic Maintenance Chemotherapy in Intermediate-Risk Rhabdomyosarcoma. JCO Oncology Advances. 2026;3(3). doi:10.1200/oa-26-00060
BibTeX
@article{Gartrell2026,
author = {Gartrell, Jessica and Patni, Tushar and Li, Yimei and Indelicato, Daniel J. and Federico, Sara M. and Davidoff, Andrew M. and Helmig, Sara and Stewart, Elizabeth and Tinkle, Christopher L. and Lucas, John T. and McCarville, Mary E. and Sandler, Eric and Albritton, Karen and Hua, Chia-ho and Pappo, Alberto S. and Krasin, Matthew J.},
title = {RMS13: A Phase II Trial Using Risk-Adapted Proton Beam Radiation and Surgery With Addition of Antiangiogenic Maintenance Chemotherapy in Intermediate-Risk Rhabdomyosarcoma},
journal = {JCO Oncology Advances},
year = {2026},
volume = {3},
number = {3},
doi = {10.1200/oa-26-00060}
}
EUVIMED